Advancing humanized monoclonal antibody for counteracting fentanyl toxicity towards clinical development
Innovative therapies to complement current treatments are needed to curb the growing incidence of fatal overdoses related to synthetic opioids. Murine and chimeric monoclonal antibodies (mAb) specific for fentanyl and its analogs have demonstrated pre-clinical efficacy in preventing and reversing dr...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Taylor & Francis Group,
2022-11-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_d5eb2b213dc94e53bb6b3a3efe917e33 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Dustin Hicks |e author |
| 700 | 1 | 0 | |a Carly Baehr |e author |
| 700 | 1 | 0 | |a Pedro Silva-Ortiz |e author |
| 700 | 1 | 0 | |a Aaron Khaimraj |e author |
| 700 | 1 | 0 | |a Diego Luengas |e author |
| 700 | 1 | 0 | |a Fatima A. Hamid |e author |
| 700 | 1 | 0 | |a Marco Pravetoni |e author |
| 245 | 0 | 0 | |a Advancing humanized monoclonal antibody for counteracting fentanyl toxicity towards clinical development |
| 260 | |b Taylor & Francis Group, |c 2022-11-01T00:00:00Z. | ||
| 500 | |a 2164-5515 | ||
| 500 | |a 2164-554X | ||
| 500 | |a 10.1080/21645515.2022.2122507 | ||
| 520 | |a Innovative therapies to complement current treatments are needed to curb the growing incidence of fatal overdoses related to synthetic opioids. Murine and chimeric monoclonal antibodies (mAb) specific for fentanyl and its analogs have demonstrated pre-clinical efficacy in preventing and reversing drug-induced toxicity in rodent models. However, mAb-based therapeutics require extensive engineering as well as in vitro and in vivo characterization to advance to first-in-human clinical trials. Here, novel murine anti-fentanyl mAbs were selected for development based on affinity for fentanyl, and efficacy in counteracting the pharmacological effects of fentanyl in mice. Humanization and evaluation of mutations designed to eliminate predicted post-translational modifications resulted in two humanized mAbs that were effective at preventing fentanyl-induced pharmacological effects in rats. These humanized mAbs showed favorable biophysical properties with respect to aggregation and hydrophobicity by chromatography-based assays, and thermostability by dynamic scanning fluorimetry. These results collectively support that the humanized anti-fentanyl mAbs developed herein warrant further clinical development for treatment of fentanyl toxicity. | ||
| 546 | |a EN | ||
| 690 | |a mab | ||
| 690 | |a opioid use disorder | ||
| 690 | |a fentanyl | ||
| 690 | |a synthetic opioids | ||
| 690 | |a humanized antibody | ||
| 690 | |a antibody characterization | ||
| 690 | |a antibody engineering | ||
| 690 | |a ptm mitigation | ||
| 690 | |a manufacturability | ||
| 690 | |a clinical development | ||
| 690 | |a Immunologic diseases. Allergy | ||
| 690 | |a RC581-607 | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Human Vaccines & Immunotherapeutics, Vol 18, Iss 6 (2022) | |
| 787 | 0 | |n http://dx.doi.org/10.1080/21645515.2022.2122507 | |
| 787 | 0 | |n https://doaj.org/toc/2164-5515 | |
| 787 | 0 | |n https://doaj.org/toc/2164-554X | |
| 856 | 4 | 1 | |u https://doaj.org/article/d5eb2b213dc94e53bb6b3a3efe917e33 |z Connect to this object online. |